Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
Sponsor: AstraZeneca
A PHASE3 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 37 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
37 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 32 earlier versions
-
Apr 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguascalientes, Mexico , Akashi, Japan , Amsterdam, Netherlands , Anaheim, United States , Asheville, United States , Baia Mare, Romania , Barcelona, Spain , Baton Rouge, United States , Bedford Park, Australia , Beijing, China and 163 more locations